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Abstract
Purpose: The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line
chemotherapy in patients with locally advanced and/or metastatic adult STS.
Patients and Methods: Eighteen patients were treated with epirubicin 30mg/m
2 on days 1 to 3 and docetaxel 100mg/m
2 on
day 1 every 3 weeks.
Results: Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%)
patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3–48 months) and the median
time to disease progression was 4 months (range, 2–45 months). Grade  3 neutropenia occurred in 88% and neutropenic
fever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred.
Discussion: Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients with
advanced STS.
Introduction
Soft tissue sarcomas (STS) represent approximately
1% of all adult malignant tumors. Clinical decisions
are based on a few well-recognized prognostic factors
such as size, location and grading.
1 Adequate
surgically local control is the treatment of choice
for STS. Radical resection or limb-sparing surgery
followed by radiotherapy has significantly improved
local control of the disease in cases of extremity
tumors.
2 However, the occurrence of distant metas-
tases remains a common clinical problem and the
main cause of death.
3
Chemotherapy is currently being used for the
treatment of locally advanced and/or metastatic STS
as also in the adjuvant setting, but only a few agents
have shown response rates of more than 15%.
Among them the most active drugs are doxorubicin
and ifosfamide as well as epirubicin, dacarbazine,
dactinomycin and methotrexate.
4
A variety of combination regimens has been
studied in phase II and III trials and most of them
have included adriamycin.
5–8 Most of these studies
have suggested that combination chemotherapy may
result in higher response rates than single-agent
doxorubicin. Epirubicin, which is an analogue of
doxorubicin with less cardiotoxicity but equal
efficacy,
9 has been used as single agent and in
combination regimens for the treatment of STS.
10–12
However, no combination regimen has been superior
to single-agent adriamycin for improving survival.
Possible explanations for the rather disappointing
results of the adriamycin-containing regimens in
advanced STS could be the relatively low dose of
anthracycline and the toxicity of those combinations.
Docetaxel is a new semisynthetic compound
enhancing microtubule assembly and inhibiting
tubulin depolymerization, resulting in cell cycle
arrest in M phase.
13 Docetaxel has been used as
a second-line chemotherapy for the treatment of
patients with adult advanced STS and has yielded
a response rate of 17%.
14 However, in another phase
II study, no responses could be detected following
treatment with docetaxel although it could be related
to the drug dose-intensity.
15 Furthermore, in another
phase II study in previously untreated patients,
docetaxel demonstrated a response rate of 11%
16,
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doxorubicin as first- and second-line chemotherapy,
docetaxel failed to demonstrate any activity against
STS.
17
The aim of this study was to evaluate the efficacy
and determine the safety of the docetaxel plus
epirubicin combination as first-line chemotherapy
in adult patients with advanced STS.
Subjects and methods
Patients and eligibility requirements
Patients aged less than 75 years, with histologically
confirmed locally advanced or metastatic STS
entered the study. Patients had to have at least one
bidimensionally measurable lesion with evidence of
progression within 6 weeks prior to treatment. Other
eligibility criteria were: ECOG performance status
(PS) 2, life expectancy of >3 months, no previous
chemotherapy or radiation therapy on target lesions,
no functionally important cardiovascular disease
(normal left ventricular ejection fraction), adequate
renal (clearance >50mL/min) and liver (bilirubin
level <2mg/dl) function, adequate bone marrow
reserve (absolute WBC count >3000/ml and platelet
count >100000/ml), absence of uncontrolled infec-
tion, no brain or leptomeningeal metastases, no
second primary malignant disease and absence
of pregnancy (Table 1). Informed consent was
obtained from all patients according to institutional
guidelines.
Histological subtypes were leiomyosarcoma
(n¼11), retroperitoneal sarcoma (n¼2), fibrosar-
coma (n¼2) and three of liposarcoma (n¼1), soft-
tissue chondrosarcoma (n¼1) and undifferentiated
sarcoma (n¼1). In four out of 11 patients with
leiomyosarcoma, the disease was located in the
uterus. None of the patients with leiomyosarcoma,
after retrospective immunohistochemical evaluation
of the specimens, proved to have gastrointestinal
stromal tumor (GIST).
Ten patients had locally advanced STS and eight
patients had metastatic disease. Sites of locally
advanced disease were the pelvis (six patients),
the extremities (five patients), the thoracic wall
(one patient), the retroperitoneum (one patient),
the abdominal cavity (two patients) and the paranasal
sinus (one patient). The lung was the most frequent
site of metastases (67%), followed by the liver (45%)
and the bones (34%).
Treatment schedule and dose modifications
Chemotherapy consisted of 30mg/m
2 epirubicin
on days 1–3 and 100mg/m
2 docetaxel on day 1.
Epirubicin (Farmorubicin; Pharmacia Italia,
S.p.A., Italy) was dissolved in distilled water at a
concentration of 5mg/ml and was administered as an
intravenous bolus infusion over a period of 5–20min
through saline infusion tubing. Docetaxel (Taxotere;
Aventis Pharma, Bridgewater, USA) was adminis-
tered as a 1h intravenous infusion. Patients also
received oral corticosteroids (methylprednisolone
32mg, 12 and 3h before and 12h after docetaxel
administration and 64mg daily on days 2–4)
and diphenhydramine hydrochloride. rhG-CSF
(Granocyte; Aventis Pharma) (5mg/kg per day s.c.)
was administered subcutaneously prophylactically
on days 4–12 in patients developing grade 3 or 4
myelosuppression after the first cycle of chemother-
apy. Antiemetic therapy consisted of ondasetron
(24mg/day) for 5 days and dexamethasone whenever
required. Treatment was repeated every 3 weeks for
a total of six cycles. Treatment was discontinued
in case of disease progression, intolerable toxicity or
patient refusal.
The NCI Common Toxicity Criteria (CTC) scale
was used for grading of adverse events and dose
modifications. A complete blood cell count was
performed twice weekly. If the neutrophil count on
the day of scheduled retreatment was <1.5 10
9/L
or the platelet count was <100 10
9/l, treatment
was postponed for 1 week without dose adjustment.
In the case of neutrophil count <0.5 10
9/l lasting
for more than 7 days or complicated with fever, or
Table 1. Patients and disease characteristics
Total number of patients enrolled 18
Assessable patients for response 15
Assessable patients for toxicity 18
Sex
Male 6
Female 12
Age (years)
Range 39–73
Median 60
WHO performance status
0.1 16
22
Histology
Leiomyosarcoma 11
Esophagus 1
Stomach 3
Colon 2
Uterus 4
Liver 1
Fibrosarcoma 2
Retroperitoneal sarcoma 2
Other 3
Pelvis 1
Breast 1
Sinus 1
Locally advanced 10
Metastatic 8
Lung 6
Liver 4
Bones 3
Prior therapy
Chemotherapy No
Radiotherapy No
Surgery 10
130platelet count <25 10
9/L, the subsequent dose
of docetaxel was reduced to 75mg/m
2 and the
subsequent dose of epirubicin was reduced to
67.5mg/m
2. In the case of left ventricular ejection
fraction decrease by 10%, treatment was continued
without epirubicin. In the case of grade 2 skin
toxicity or neurotoxicity, a 25% reduction of the
docetaxel was required. Docetaxel would be stopped
in the case of persistent grade 2 skin reactions and
grade 3 neurotoxicity. In the case of fluid retention,
no dose reduction of docetaxel was planned,
although treatment with 50mg of spironolactone
would be recommended.
Response criteria
Evaluation of response was carried out according to
World Health Organization scale. Initial evaluation
included a thorough medical history and physical
examination, complete blood count with differential,
biochemistry profile and clotting studies.
Pretreatment imaging evaluation included: chest X-
ray, computed tomography (CT) scans of the lungs
and abdomen, whole body ultrasound, bone scinti-
graphy, ECG and echocardiogram or MUGA.
Additional CT scan or MRIs were performed if
clinically indicated. During treatment, clinical and
hematology laboratory evaluation were performed
every 3 weeks. Imaging studies were made at
baseline, after cycle 3 and at the end of chemother-
apy or even earlier if there was clinical or other
evidence of relapse.
Statistical analysis
Time to event curves was estimated using the
Kaplan–Meier method. Survival was calculated
from the date of registration to the date of death,
irrespective of its cause. The duration of partial
response or stable disease was calculated from the
first documentation of response until the date of
radiologically documented progression. Time to
disease progression was determined by the interval
between the initiation of therapy to the first date that
disease progression was objectively documented.
The study followed Simon’s two-stage optimal
design. A response rate of more than 20% was the
cut-off for considering the schedule sufficiently
active. The first step consisted of 18 patients. If
more than three responses were observed, accrual
was to continue to a total of 35 patients with a 5%
rejection error and a power of 90%.
Results
Patient demographics
Between January 1997 and April 2001, 18 che-
motherapy- and radiation-naı ¨ve patients with locally
advanced or metastatic soft tissue sarcomas con-
sented to participate in the study (Table 1). Their
median age was 60 years and 16 of them had an
ECOG PS of 0-1. Eleven (61%) patients had
leiomysarcoma. Additionally, 10 (55.5%) patients
had locally advanced and eight (44.4%) metastatic
disease.
Drug delivery
A total of 70 chemotherapy courses were adminis-
tered with a median number of four cycles/patient
(range 1–6). Six (33.3%) patients only completed six
cycles of the treatment. The median delivered dose
intensity was 39.6mg/m
2/week for docetaxel
and 35.7mg/m
2/week for epirubicin, corresponding
to 99 and 99% of the protocol-planned doses,
respectively.
Efficacy of treatment
In an intention-to-treat analysis, no complete
response was observed, while partial response was
achieved in three patients (20%, 95%CI:3.0–43%).
Partial responses were observed in a patient with
soft-tissue chondrosarcoma, a patient with uterus
leiomyosarcoma and another with undifferentiated
sarcoma. Three patients (20%, 95%CI:3.0–43%)
had stable disease and nine (60%, 95%CI: 32–88%)
progressive disease. The median time to disease
progression was 4 months (range, 2–45 months), and
the overall median survival of all patients was 14
months (range, 3–48 months) (Fig. 1). The 1-year
survival was 73% (95%CI:48–99%). The median
time to disease progression for the three responding
patients was 12 months (range, 8–45 months) and
the median overall survival 26 months (range, 4–48
months).
Overall survival in months
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Fig. 1. Overall survival of the patients enrolled in the study.
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All patients were assessed for toxicity. No toxic
death occurred. The major adverse reaction was
hematological toxicity (Table 2). Neutropenia was
recorded in all patients; grade 2 in two (11.1%)
patients, grade 3 in eight (44.4%) patients and grade
4 in eight (44.4%) patients. Neutropenic fever that
required administration of antibiotics, was reported
in five (27.8%) patients. Anemia was mild; six
(33.3%) patients experienced grade 1 and two
(11.1%) patients grade 2. There was no case of
thrombocytopenia. In three (16.7%) patients, sub-
sequent dose reduction of the chemotherapeutic
agents was required due to prolonged myelotoxicity.
Grade 1 neurotoxicity was recorded in five
(27.8%) patients; one patient presented grade 2
neurosensory defects and neuromotor symptoms and
required reduction of docetaxel dose. Treatment-
related nausea and vomiting was reported in six
(33.3%) patients, but only one patient reported
grade 3 toxicity requiring the addition of dexametha-
sone. Furthermore, two (11.1%) patients demon-
strated grade 1 stomatitis, one (5.5%) patient grade 1
diarrhea, and three (16.7%) patients complained
of mild constipation. Alopecia grade 3 related
to chemotherapy was observed in nine (50%)
patients. No patient demonstrated skin reactions.
One patient presented fluid retention syndrome with
edema and pleural effusion with no delay in the
treatment schedule.
Discussion
The aim of this study was to evaluate the clinical
efficacy and toxicity of the docetaxel and epirubicin
combination as first-line chemotherapy in advanced
adult soft tissue sarcomas. Initial phase II studies
involving patients with advanced STS have demon-
strated response rates on docetaxel treatment of 11
and 17%.
14,16 The rationale for the combination of
docetaxel and epirubicin is based on their activity
against STS, their limited cross-resistance as well as
the different but potentially synergistic mechanisms
of action, and the promising results of the combina-
tion treatment in other malignancies such as breast
cancer.
18 Both anthracyclines and taxanes are known
to have a dose–response relationship and some
overlapping toxicities, so the combined use of both
agents results in an enhanced toxicity profile. We
chose the 3-day schedule of epirubicin in order
to achieve better clinical outcome and reduce
dose-dependent toxicities.
This trial could not meet the predefined efficacy
criteria. A possible explanation of the low response
rate observed following the administration of doc-
etaxel together with epirubicin may be partly
attributed to the limited activity of docetaxel in
STS and the high percentage of patients enrolled
with leiomyosarcomas of retroperitoneal and visceral
origin (61.1%),
19 while only 4 patients (22%) had
uterine leiomyosarcomas. The limited activity of
docetaxel as first-line chemotherapy agent in
advanced STS was also outlined in a randomized
study comparing docetaxel versus doxorubicin
with optimal dose-intensity.
17 However, docetaxel
seems to represent an efficacious and tolerable
treatment in patients with uterine leiomyosarcomas
in combination with gemcitabine.
20
Another limitation of our study was the consider-
able myelosuppression associated with the che-
motherapy regimen, although no toxic death
occurred. Indeed, neutropenia was the immediate
dose-limiting toxicity. Neutropenia appeared in
almost all patients and it was grades 3 and 4 in 16
of the patients (88.9%). Neutropenic fever was
observed in five (27.8%) patients, and in three
(16.7%) patients the dose was reduced because of
prolonged myelotoxicity. Docetaxel was adminis-
tered at the maximum accepted dose according to
pharmacokinetic studies.
21,22 Therefore, this study
seems to provide the best results that can be obtained
in terms of dose–response effect. In addition, dose
escalation of epirubicin could possibly increase the
risk of cardiotoxicity. Fluid retention syndrome
represents a common toxicity of docetaxel, but it
was demonstrated in only one patient while hyper-
sensitivity reactions did not occur. The prophylactic
use of corticosteroids might explain the low inci-
dence of these adverse reactions. The majority of
patients did not experience other significant toxi-
cities, except in one patient with a grade 2
neurosensory and neuromotor adverse event who
required reduction of docetaxel dose.
To summarize, the present study demonstrates
that the combination of docetaxel with epirubicin
for the treatment of patients with advanced STS
has considerable myelotoxicity and rather low
efficacy, and should not be used in adult soft tissue
sarcomas.
Table 2. Toxicity profile
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 0 2 8 8
Febrile neutropenia 0 0 5 0
Anemia 6 2 0 0
Alopecia 3 6 9 0
Nausea/vomiting 3 2 1 0
Fatigue 6 3 0 0
Stomatitis 2 0 0 0
Constipation 2 1 0 0
Diarrhea 1 0 0 0
Neuromotor
side effects
0100
Neurosensory
side effects
5100
Fluid retention
syndrome
1000
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